---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024471"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:15:27.499210+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp

## Summary
- Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.
- Loss driven by increased stock-based compensation related to pre-IPO acquisition of pharmaceutical distribution unit.
- President/Interim-CEO Prashant Patel reappointed Oct 6; refocusing on EinsteinRx and Brenzavvy diabetes launch.
- Acquisition of Peek Healthcare Technologies terminated as no longer strategically aligned.
- Advanced discussions with DataVault AI (DVLT) for blockchain license in Q4 2025/Q1 2026.

## SEC filing metadata
- accession: 0001493152-25-024471
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315225024471/0001493152-25-024471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315225024471/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024471
- JSON: https://secwatch.observer/filing/0001493152-25-024471.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024471.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.